ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Between January 2013 and ...
Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma. This is an ASCO Meeting Abstract from the 2016 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results